Back to results
US 8,187,874 B2Granted
Drug discovery method
AssigneeVertex Pharmaceuticals Incorporated
InventorsRobert B. Perni, Cynthia Gates, John Thomson
Life of this patent
Estimating the term…
Abstract
The present invention relates to drug discovery methods, particularly antiviral drug discovery methods.
Claims16
A method for identifying a compound having activity against a Hepatitis C Virus (HCV), comprising:
- (a) contacting compounds with a target in the HCV;
- (b) determining whether or not said compounds bind reversibly with the target, wherein the target is an HCV enzyme selected from the group consisting of a protease, a helicase, and a polymerase;
- (c) measuring the half-life of compounds bound to the target;
- and
- (d) selecting a compound having activity against HCV based on the reversible binding property and on the half-life of compounds bound to the target, wherein a compound that binds reversibly to the target and has a half-life bound to the target of at least about 25% of the half-life of the replication cycle of HCV is identified as a compound having activity against HCV.
2 more elements
A method for identifying a compound having activity against a Hepatitis C Virus (HCV), comprising:
- (a) contacting compounds with a target in the HCV, wherein the target is an HCV enzyme selected from the group consisting of a protease, a helicase, and a polymerase;
- (b) determining whether or not said compounds bind reversibly with the target;
- (c) measuring the half-life of the compounds bound to the target;
- and
- (d) selecting a compound having activity against HCV based on the reversible binding property and based on the half-life of compounds bound to the target, wherein a compound that has a half-life bound to the target of about 25% to about 300% of the half-life of the replication cycle of HCV is identified as a compound having activity against HCV.
2 more elements
A method for identifying a compound having activity against a Hepatitis C Virus (HCV), comprising:
- (a) contacting compounds with a target in the HCV, wherein the target is an HCV enzyme selected from the group consisting of a protease, a helicase, and a polymerase;
- (b) determining whether or not said compounds bind reversibly with the target;
- (c) measuring the half-life of the compounds bound to the target;
- and
- (d) selecting a compound having activity against HCV based on the reversible binding property and based on the half-life of compounds bound to the target, wherein a compound that has a half-life bound to the target of between 10 minutes and 6 hours is identified as a compound having activity against HCV.
2 more elements
Dependencies are inferred from the claim text.